R

R&G PharmaStudies Co Ltd
SZSE:301333

Watchlist Manager
R&G PharmaStudies Co Ltd
SZSE:301333
Watchlist
Price: 58.41 CNY -2.81% Market Closed
Market Cap: 5.6B CNY
Have any thoughts about
R&G PharmaStudies Co Ltd?
Write Note

R&G PharmaStudies Co Ltd
Other Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

R&G PharmaStudies Co Ltd
Other Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
R
R&G PharmaStudies Co Ltd
SZSE:301333
Other Current Assets
ÂĄ5.1m
CAGR 3-Years
-25%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Other Current Assets
ÂĄ300.9m
CAGR 3-Years
-8%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Other Current Assets
ÂĄ268.2m
CAGR 3-Years
39%
CAGR 5-Years
42%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Other Current Assets
ÂĄ1.5B
CAGR 3-Years
-3%
CAGR 5-Years
29%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Other Current Assets
ÂĄ127.9m
CAGR 3-Years
16%
CAGR 5-Years
15%
CAGR 10-Years
-8%
W
WuXi XDC Cayman Inc
HKEX:2268
Other Current Assets
ÂĄ119.8m
CAGR 3-Years
89%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

R&G PharmaStudies Co Ltd
Glance View

Market Cap
5.6B CNY
Industry
Life Sciences Tools & Services

R&G PharmaStudies Co., Ltd. engages in the provision of clinical trial outsourcing services. The company is headquartered in Beijing, Beijing and currently employs 1,926 full-time employees. The company went IPO on 2022-08-02. The firm's main businesses include clinical trial operation services (CO Services), clinical trial site management services (SMO Services), biological sample testing services (BA Services), data management and statistical analysis services (DM/ST Services), clinical trials Consulting Services, Clinical Pharmacology Services (CP Services) and others. The firm operates its businesses primarily in the domestic market.

Intrinsic Value
57.24 CNY
Overvaluation 2%
Intrinsic Value
Price
R

See Also

What is R&G PharmaStudies Co Ltd's Other Current Assets?
Other Current Assets
5.1m CNY

Based on the financial report for Dec 31, 2023, R&G PharmaStudies Co Ltd's Other Current Assets amounts to 5.1m CNY.

What is R&G PharmaStudies Co Ltd's Other Current Assets growth rate?
Other Current Assets CAGR 3Y
-25%

Over the last year, the Other Current Assets growth was 5%. The average annual Other Current Assets growth rates for R&G PharmaStudies Co Ltd have been -25% over the past three years .

Back to Top